Dapagliflozin reduces hyperkalaemia risk in heart failure with reduced EF: Study
Patients with heart failure and reduced ejection fraction (HFrEF) and taking a mineralocorticoid receptor antagonists (MRA) who were randomized to dapagliflozin had half the incidence of moderate/severe hyperkalaemia, compared with those randomized to placebo,a recent study has suggested.
Researchers have presented the findings in European Society of Cardiology virtual congress.
Spironolactone and eplerenone are both mineralocorticoid-receptor antagonists. These compounds block both the epithelial and nonepithelial actions of aldosterone, with the latter assuming increasing clinical relevance.
The mineralocorticoid receptor antagonists (MRAs), spironolactoneand eplerenone, are recommended for patients with symptomatic heart failure with ejection fraction of 35% or less. Owing to their capacity to lower blood pressure and to reduce the risk of cardiovascular complications and mortality in large randomized, placebo‐controlled trials ,MRAs are documented to be effective in such patients.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.